Aortic Aneurysm Market : Forecasts Report Till 2031

Visiongain has published a new report on Aortic Aneurysm Market Report : Forecasts by Type (TAA, AAA), by Product (Stent Grafts, Catheters), by Treatment (EVAR, OSR), by End User (Hospitals & Clinics, ASCs) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Aortic Aneurysm Companies AND COVID-19 Recovery Scenarios.

Global aortic aneurysm market was valued at US$xx billion in 2020 and is projected to reach at a market value of US$xx million by 2031

Download Exclusive Sample of Report: To Know the Impact of COVID-19 On This Industry @ https://www.visiongain.com/report/aortic-aneurysm-market-2021/

COVID-19 Impact on Aortic Aneurysm Market
The ongoing COVID-19 pandemic is putting a huge strain on health-care systems around the world, forcing even the most established hospitals to reconsider their treatment options. Due to a lack of available intensive care unit (ICU) beds, most medical centers have restricted or cancelled elective surgical procedures entirely. Endovascular repair is without a doubt the treatment option in the unfortunate event of a ruptured AAA (rAAA) and/or concomitant COVID-19 infection, as identified in other recent guidelines.

How the Aortic Aneurysm Market report helps you
In summary, our 360+ page report provides you with the following knowledge:

• Revenue forecasts to 2031 for Aortic Aneurysm Market, with forecasts for Type, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues. Abdominal aortic aneurysm (AAA) segment accounts for the major share of the global aortic aneurysm market in 2020 while thoracic aortic aneurysm (TAA) segment is expected to be the fastest growing market during the forecast period.
• Revenue forecasts to 2031 for Aortic Aneurysm Market, with forecasts for Product, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues. Stent grafts segment accounts for the major share of the global aortic aneurysm market in 2020 while catheters segment is expected to be the fastest growing market during the forecast period.
• Revenue forecasts to 2031 for Global Aortic Aneurysm Market, with forecasts for Treatment, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues. Endovascular aneurysm repair (EVAR) segment accounts for the major share of the global aortic aneurysm market in 2020 while open surgical repair (OSR) segment is expected to be the fastest growing market during the forecast period.
• Revenue forecasts to 2031 for Aortic Aneurysm Market, with forecasts for End User, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues. Hospitals & clinics segment accounts for the major share of the global aortic aneurysm market in 2020 while ambulatory surgery centers (ASCs) segment is expected to be the fastest growing market during the forecast period.

Get Detailed TOC @ https://www.visiongain.com/report/aortic-aneurysm-market-2021/

• Revenue forecasts to 2031 for 5 regional and 16 key national markets – See forecasts for the aortic aneurysm market in North America, Europe, Asia-Pacific, Latin America and Middle East and Africa. Also forecasted is the market in the US, Canada, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, and Australia among other prominent economies. There will be growth in both established and in developing markets. Our analyses show that the U.S. would continue dominating the global aortic aneurysm market while India is poised to grow at a double digit CAGR during the forecast period, 2021 to 2031.

Prospects for established firms and those seeking to enter the market– including company profiles for 14 of the major companies involved in the Aortic Aneurysm Market. Some of the company’s profiled in this report include:

• Medtronic plc
• Cardinal Health, Inc.
• W. L. Gore & Associates, Inc.
• Cook Medical
• JOTEC GmbH
• Terumo Corporation
• Cardiatis
• Endologix, Inc.
• Endospan
• LifeTech Scientific Corporation
• Getinge AB
• Arsenal Medical, Inc.
• Lombard Medical Limited

Market Drivers

High tobacco smoking prevalence in the developing and developed countries
Smoking significantly raises the risk of AAA. The risk is proportional to the number of years spent smoking and the number of years spent smoking after quitting. Tobacco use harms nearly every organ in the body and is the leading cause of preventable death. In 2016, smoking was responsible for more than 7.1 million deaths worldwide (12.5 percent of all deaths). According to the WHO, tobacco will kill 8 million people every year by 2030. Tobacco is estimated to have killed around 40 million people in the developed world between 2005 and 2030. This number is more than three times higher in the developing world, at around 135 million. Although smoking prevalence is declining in some LMICs (Low- and Middle-Income Countries), the developing world's relatively high population growth means that the number of smokers, and thus the number of deaths and diseases caused by smoking, will continue to rise.

Rise in geriatric population
Abdominal aortic aneurysm (AAA) is uncommon in people under the age of 60. AAA affects about one out of every 1000 people between the ages of 60 and 65, and the number continues to rise as people get older. AAAs are found in 2 to 13% of men and 6% of women over the age of 65, according to screening studies. However, nearly 90% of aneurysms discovered through screening are small (less than 3.5 cm in diameter) and unlikely to rupture.

According to the 2019 Revision of the World Population Prospects, by 2050, one in six people will be over the age of 65 (16%), up from one in eleven in 2019. (9 percent). By 2050, one in every four people in Europe and North America will be 65 or older. For the first time in history, people aged 65 and up outnumbered children under the age of five on a global scale in 2018. The number of people aged 80 and up is expected to triple by 2050, from 143 million in 2019 to 426 million.

The importance of AAA screening is becoming more widely recognized
The high prevalence of infrarenal AAA in subgroups of patients, as well as its asymptomatic course until rupture, demonstrate the importance of screening. Ultrasonography is an excellent tool for screening and surveillance that is both risk-free and inexpensive. In the multicentre aneurysm screening study, over 67,000 male subjects aged 65 to 74 years were randomized for ultrasound screening for infrarenal AAA and subsequent surgical treatment of aneurysms larger than 54 mm.

Request Customized Report as Per Your Requirements @ https://www.visiongain.com/contact/

Market Opportunities

New 3D technology can now repair aneurysms that were previously thought to be inoperable
Repairing a thoracoabdominal aortic aneurysm is a difficult procedure that can be fraught with complications. Contrast dyes, which are required to identify the locations of major vessels that originate near or from life-threatening arterial bulges, cause renal problems in up to 25% of vascular patients.

Surgeons at UC San Diego Health are using a new imaging technology that uses artificial intelligence and machine learning to reduce the need for contrast agents, the time spent in surgery, and the risk of post-operative kidney complications. UC San Diego Health is one of the first health-care systems in the country to use the software. In traditional endovascular aortic aneurysm repair, surgeons use contrast dyes to reveal the size and scope of the aneurysm, then use X-rays to guide a plastic or fabric-coated metal tube stent graft to the weakened section of the arterial wall to prevent it from tearing.

The new Dynamic Morphology Correction technology, developed by Cydar Medical in the United Kingdom, allows surgeons to work more precisely and quickly with less contrast dye. Rather, surgeons rely on dynamic 3D image overlays of the human body, which are created using computerized prediction models based on the patient's pre-operative X-ray and anatomy. The models allow surgeons to reduce iodine contrast and its risk to the kidneys, lower radiation exposure during surgery, and spend less time on the operating table.

Patients and doctors now have a new, less invasive option for AAA treatment thanks to innovative AAA devices
Patients and doctors now have a new, less invasive option with the AAA device. Cordis Corporation has released the INCRAFT AAA Stent Graft System (INCRAFT System), an ultra-low-profile endovascular aneurysm repair (EVAR) device for patients with infrared abdominal aortic aneurysms (AAA). The INCRAFT System has been approved for use in Europe and Canada, and it is now available for purchase. This device is a step forward in the field of EVAR, and it offers a new option for patients and doctors looking for a less invasive way to treat AAA.

The INCRAFT system is an appealing new EVAR device option because of its ultra-low-profile design and customization, which allows doctors to consider this less invasive procedure for many patients, especially those with smaller vasculature who might be ineligible for EVAR otherwise. The INNOVATION Trial in Europe on the INCRAFT system recently published two-year data that showed excellent performance by adding supporting scientific data to the device. With the launch of the INCRAFT System, Cordis is bringing an innovative advancement to the EVAR field while also entering a growth segment that diversifies the company's strong product portfolio.

Competitive Landscape
Some of the companies profiled in the report include Medtronic plc, W.L. Gore & Associates, Inc., JOTEC GmbH, Cook Medical, Cardinal Health, Inc., Terumo Corporation, and Cardiatis. For example, Terumo Corporation decided to buy Aortica Corporation, a company based in the US dedicated to advancing the science of personalised vascular therapy, in November 2019. During Fenestrated Endovascular Aortic Repair, Aortica developed AortaFit, an automated case planning software that precisely matches fenestrations on an endograft with the unique locations of each individual patient's branch arteries (FEVAR). Endovascular treatment of complex abdominal aortic aneurysms can result in endoleaks and migration, so the new technology aims to improve graft anchoring while reducing the risk of endoleaks and migration (AAA). Terumo Aortic will be able to accelerate the development of a first-in-class, purpose-built FEVAR System as a result of this acquisition, particularly in the US. This will helped the company to transform vascular disease management in this difficult patient population by combining the AortaFit System and BoulEVARd covered stent graft with the proven capabilities of TREO.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

Find More Other Industry Research Reports by Visiongain:

• Pharma Industry Reports
• Energy Industry Reports
• Aviation Industry Reports

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help:

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent market research company in Europe, the company comprises over 400+ analysts and consultants, adding more than 1400 market research reports to its vast database each year. These reports offer in-depth analysis on 18 industries worldwide. With the help of an interactive market intelligence platform, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. 

Contact:
Sara Peerun
Commercial Director
Visiongain Limited
Phone: +44 (0) 20 7549 9987.
Email: sara.peerun@visiongain.com

Follow us

LinkedIn | Facebook | Twitter